Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 18/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.78 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4913541 | 0.88 | MCHR1 (0.70) | MCHR1KCNH2CHRM2CYP3A4 | |
| SCHEMBL4918264 | 0.88 | MCHR1 (1.00) | MCHR1KCNH2CHRM2CYP3A4KDM4E | |
| SCHEMBL4923710 | 0.85 | KCNH2 (0.65) | MCHR1KCNH2CHRM2KDM4EALDH1A1 | |
| SCHEMBL5316462 | 0.83 | MCHR1 (0.65) | MCHR1KCNH2CYP3A4 | |
| SCHEMBL4913448 | 0.82 | MCHR1 (0.67) | MCHR1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL27710070 | 0.81 | MCHR1 (0.63) | MCHR1KCNH2CYP3A4 | |
| SCHEMBL4913438 | 0.81 | MCHR1 (0.64) | MCHR1KCNH2CHRM2 | |
| SCHEMBL4917713 | 0.81 | MCHR1 (0.58) | MCHR1KCNH2CYP3A4 | |
| SCHEMBL5343940 | 0.81 | MCHR1 (0.86) | MCHR1KCNH2CHRM2CYP3A4KDM4E | |
| SCHEMBL4925522 | 0.80 | MCHR1 (0.67) | MCHR1KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | claimed |
| EP-1831194-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | claimed |
| WO-2006068594-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | claimed |
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1831194-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006068594-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | MCHR1, MCHR2, MC1R | MCHR1 1/4885KCNH2 1440/4885CHRM2 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.